Ensuring Equal Access to Treatments Act of 2017
A BILL
To amend title XVIII of the Social Security Act to provide for improvements to coverage and payment under the Medicare program for new drugs, devices, and technology.
Sec. 2 Coverage and payment for new drugs, devices, and technology under the Medicare program
“(x)
“(I) An individual or entity that submits an application for additional payment under this subparagraph for a new technology shall be entitled to administrative review of an adverse determination by the Secretary with respect to such application.
“(II) The Secretary shall establish a process for administrative review for purposes of subclause (I). Under such process, administrative review shall be conducted by the Departmental Appeals Board of the Department of Health and Human Services. Under such process, the Departmental Appeals Board shall complete administrative review within 90 days of the date of receipt of the request for such review.”
“(M) Limit on aggregate annual adjustment
“(i) In general—The total of the additional payments made under subparagraphs (K) and (L) for covered services furnished for discharges in a fiscal year (as estimated by the Secretary before the beginning of the fiscal year) may not exceed the applicable percentage (specified in clause (ii)) of the total program payments estimated to be made under this subsection for all covered services furnished for discharges in that fiscal year. If this clause is first applied to less than a full fiscal year, the previous sentence shall apply only to the portion of such fiscal year.
“(ii) Applicable percentage—For purposes of clause (i), the term ‘“applicable percentage”’ for fiscal year 2019 and each subsequent fiscal year, is a percentage specified by the Secretary up to (but not to exceed) 2.0 percent.
“(iii) Uniform prospective reduction if aggregate limit projected to be exceeded—If the Secretary estimates before the beginning of a fiscal year that the amount of the additional payments under subparagraphs (K) and (L) for the fiscal year (or portion thereof) as determined under clause (i) without regard to this clause will exceed the limit established under such clause (i), the Secretary shall reduce pro rata the amount of each of the additional payments under this paragraph for that fiscal year (or portion thereof) in order to ensure that the aggregate additional payments under subparagraphs (K) and (L) (as so estimated) do not exceed such limit.”
“(I) the Secretary shall create additional groups of covered OPD services that classify separately procedures and services that employ medical devices and drugs described in a subparagraph of paragraph (22), in accordance with such paragraph.”
“(22) Separate additional payment groups for certain drugs and devices previously eligible for pass-through payments—For purposes of paragraph (2)(I), the following shall apply:
“(A) In general—For payments under this subsection for services furnished on or after January 1, 2020, the Secretary shall, in accordance with subparagraph (B), create additional groups of covered OPD services to classify separately from other covered OPD services the following:
“(i) Existing pass-through drugs and devices—Medical devices and drugs that met the requirements of paragraph (6)(A)(iv) and were receiving payment under paragraph (6) by reason of satisfying such requirements beginning on or after the date of enactment of this paragraph.
“(ii) Retired pass-through drugs and devices—Medical devices and drugs that had met the requirements of paragraph (6)(A)(iv) and were receiving payment under paragraph (6) by reason of satisfying such requirements before the date of enactment of this paragraph but after January 1, 2010.
“(B) Considerations—In carrying out subparagraph (A), the Secretary shall—
“(i) bundle procedures and services that employ a device to which such subparagraph applies with all relevant diagnostic tests and surgical procedures, as applicable;
“(ii) bundle procedures and services that employ a drug, with respect to which payment is not made on or after the date specified in subparagraph (A) in accordance with the methodology under section 1847A and to which such subparagraph applies, with all relevant diagnostic tests and surgical procedures, as applicable; and
“(iii) include such relevant diagnostic tests and surgical procedures in more than one group created under such subparagraph, as necessary.”
“(F) Appeals process
“(i) In general—An individual or entity that submits an application for additional payment under this paragraph for a new technology shall be entitled to administrative review of an adverse determination by the Secretary with respect to such application.
“(ii) Process—The Secretary shall establish a process for administrative review for purposes of clause (i). Under such process, administrative review shall be conducted by the Departmental Appeals Board of the Department of Health and Human Services. Under such process, the Department official involved shall complete administrative review within 90 days of receipt of a request for such review.”